Phase II clinical-laboratory of the anti-angiogenesis receptor tyrosine kinase (RTK) inhibitor, SU5416 in refractory acute myelogenous leukemia (AML) and myelodysplasia (MDS).

被引：0

作者：

Karp, JE

Stopeck, A

Albitar, M

Silverman, L

Lancet, JE

Jacobs, M

Ofarrell, M

Hannah, A

Cherrington, J

Giles, FJ

机构：

[1] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD USA

[2] Univ Arizona, Ctr Canc, Houston, TX USA

[3] MD Anderson Canc Ctr, Houston, TX USA

[4] Mt Sinai Med Ctr, New York, NY 10029 USA

[5] Univ Rochester, Ctr Canc, Rochester, NY USA

[6] Sugen Inc, S San Francisco, CA USA

来源：

BLOOD | 2001年 / 98卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

495

引用

页码：118A / 118A

页数：1

共 10 条

[1] Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
Mendel, DB
Laird, AD
Smolich, BD
Blake, RA
Liang, CX
Hannah, AL
Shaheen, RM
Ellis, LM
Weitman, S
Shawver, LK
Cherrington, JM
ANTI-CANCER DRUG DESIGN, 2000, 15 (01): : 29 - 41
[2] Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
Mesters, RM
Padró, T
Bieker, R
Steins, M
Kreuter, M
Göner, M
Kelsey, S
Scigalla, P
Fiedler, W
Büchner, T
Berdel, WE
BLOOD, 2001, 98 (01) : 241 - 243
[3] SU5416, a receptor tyrosine kinase inhibitor, is active in preclinical models of acute myeloid leukemia.
Bertolini, F
Dell'Agnola, C
Gobbi, A
Monestiroli, S
Pruneri, G
McMahon, G
Martinelli, G
BLOOD, 2000, 96 (11) : 117A - 117A
[4] SU5416,a novel receptor tyrosine kinase inhibitor, in the treatment of patients with refractory, c-kit positive, acute myeloid leukemia.
Fiedler, W
Mesters, R
Staib, P
Kuse, R
Duehrsen, U
Flasshove, M
Truemper, L
Cavalli, F
Ottmann, O
Kelsey, S
Scigalla, P
Loges, S
Tinnefeld, H
Hossfeld, DK
Berdel, WE
BLOOD, 2001, 98 (11) : 124A - 124A
[5] SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
Giles, FJ
Stopeck, AT
Silverman, LR
Lancet, JE
Cooper, MA
Hannah, AK
Cherrington, JM
O'Farrell, AM
Yuen, HA
Louie, SG
Hong, W
Cortes, JE
Verstovsek, S
Albitar, M
O'Brien, SM
Kantarjian, HM
Karp, JE
BLOOD, 2003, 102 (03) : 795 - 801
[6] Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia
O'Farrell, AM
Yuen, HA
Smolich, B
Hannah, AL
Louie, SG
Hong, WR
Stopeck, AT
Silverman, LR
Lancet, JE
Karp, JE
Albitar, M
Cherrington, JM
Giles, FJ
LEUKEMIA RESEARCH, 2004, 28 (07) : 679 - 689
[7] Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma
Zangari, M
Anaissie, E
Stopeck, A
Morimoto, A
Tan, N
Lancet, J
Cooper, M
Hannah, A
Garcia-Manero, G
Faderl, S
Kantarjian, H
Cherrington, J
Albitar, M
Giles, FJ
CLINICAL CANCER RESEARCH, 2004, 10 (01) : 88 - 95
[8] Phase II study of SU5416 - a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - in patients with refractory myeloproliferative diseases
Giles, FJ
Cooper, MA
Silverman, L
Karp, JE
Lancet, JE
Zangari, M
Shami, PJ
Khan, KD
Hannah, AL
Cherrington, JM
Thomas, DA
Garcia-Manero, G
Albitar, M
Kantarjian, HM
Stopeck, AT
CANCER, 2003, 97 (08) : 1920 - 1928
[9] HEC73543 is a novel potent, selective Flt3 receptor tyrosine kinase (RTK) Inhibitor for the treatment of refractory acute myeloid leukemia (AML)
Cheng, Cliff
CANCER RESEARCH, 2017, 77
[10] A randomized phase II trial of the tyrosine kinase inhibitor PKC412 in patients (pts) with acute myeloid leukemia (AML)/high-risk myelodysplastic syndromes (MDS) characterized by wild-type (WT) or mutated FLT3.
Estey, EH
Fisher, T
Giles, F
Feldman, EJ
Ehninger, G
Schiller, GJ
Klimek, VM
Nimer, SD
De Angelo, DJ
Gilliland, DG
Fox, E
Wang, YF
Rosamilia, M
Resta, D
Cohen, P
Stone, RM
BLOOD, 2003, 102 (11) : 614A - 615A

← 1 →